


Edited by Jörg Knäblein

 WILEY-VCH

# Modern Biopharmaceuticals

Design, Development and Optimization

Volume 4



included

Dedicated to Francis Crick (1916–2004)



# **Modern Biopharmaceuticals**

Volume 4

Design, Development and Optimization

*Edited by*  
*Jörg Knäblein*



**WILEY-  
VCH**

WILEY-VCH Verlag GmbH & Co. KGaA

**Editor****Dr. Jörg Knäblein**

Head Microbiological Chemistry  
Schering AG  
Müllerstraße 178  
13342 Berlin  
Germany

All books published by Wiley-VCH are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

**Library of Congress Card No.:**

applied for

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library

**Bibliographic information published by****Die Deutsche Bibliothek**

Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the Internet at <http://dnb.ddb.de>.

© 2005 WILEY-VCH Verlag GmbH & Co. KGaA,  
Weinheim

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Printed in the Federal Republic of Germany  
Printed on acid-free paper

**Cover** Tim Fonseca, [www.fonsecatim.com](http://www.fonsecatim.com)  
**Typesetting** K+V Fotosatz GmbH, Beerfelden  
**Printing** betz-druck GmbH, Darmstadt  
**Bookbinding** J. Schäffer GmbH, Grünstadt

**ISBN-13** 978-3-527-31184-2

**ISBN-10** 3-527-31184-X

*Jörg Knäblein (Ed.)*

**Modern Biopharmaceuticals**

## *Further Titles of Interest*

Gary Walsh

**Biopharmaceuticals**  
**Biochemistry and Biotechnology**

2003

ISBN 0-470-84326-8

Oliver Kayser, Rainer H. Müller (Eds.)

**Pharmaceutical Biotechnology**  
**Drug Discovery and Clinical Applications**

2004

ISBN 3-527-30554-8

Gary Walsh

**Proteins**  
**Biochemistry and Biotechnology**

2001

ISBN 0-471-89907-0

Rainer Fischer, Stefan Schillberg (Eds.)

**Molecular Farming**  
**Plant-made Pharmaceuticals and Technical Proteins**

2004

ISBN 3-527-30786-9

Rodney J. Y. Ho, Milo Gibaldi

**Biotechnology**  
**and Biopharmaceuticals**  
**Transforming Proteins and Genes into Drugs**

2003

ISBN 0-471-20690-3

Martin Schleef (Ed.)

**DNA-Pharmaceuticals**  
**Formulation and Delivery in Gene Therapy**  
**and DNA Vaccination**

2005

ISBN 3-527-31187-4

Chi-Huey Wong (Ed.)

**Carbohydrate-based**  
**Drug Discovery**

2003

ISBN 3-527-30632-3

Rolf D. Schmid, Ruth Hammelehle

**Pocket Guide to Biotechnology**  
**and Genetic Engineering**

2003

ISBN 3-527-30895-4

## Contents

### Volume 1

Prologue XXV

Dedication XXIX

Foreword XXXI

Foreword XXXV

Quotes XXXVII

Executive Summary XLI

List of Contributors CXXIII

#### Introduction

Current Status of Biopharmaceuticals: Approved Products and Trends in Approvals 1  
*Gary Walsh*

#### Part I Biopharmaceuticals Used in Molecular Medicine

From Genome to Clinic – Correlation Between Genes, Diseases and Biopharmaceuticals 37

1 Beginning to Understand the End of the Chromosome 37  
*Thomas R. Cech*

2 The Role of Pharmacogenetics/Pharmacogenomics  
in Drug Development and Regulatory Review: Current Status 49  
*Shiew-Mei Huang and Lawrence J. Lesko*

- 3      **Large-scale Detection of Genetic Variation: The Key to Personalized Medicine** 71  
*Joerg Geistlinger and Peter Ahnert*
  
- 4      **A Systems Biology Approach to Target Identification and Validation  
for Human Chronic Disease Drug Discovery** 99  
*Bonnie E. Gould Rothberg, Carol E. A. Peña, and Jonathan M. Rothberg*
  
- 5      **The Development of Herceptin®:  
Paving the Way for Individualized Cancer Therapy** 127  
*Thorsten S. Gutjahr and Carsten Reinhardt*
  
- siRNA – the Magic Bullet and Other Gene Therapeutical Approaches** 151
  
- 6      **Adenovirus-based Gene Therapy: Therapeutic Angiogenesis  
with Adenovirus 5 Fibroblast Growth Factor-4 (Ad5FGF-4) in Patients  
with Chronic Myocardial Ischemia** 151  
*Michael McCaman, Francisco J. Castillo, Farah Fawaz, Yasushi Ogawa, Erik Whiteley,  
Elisabeth Lehmborg, Mei Tan, Jacob Kung, Bruce Mann, Erno Pungor Jr.,  
and Gabor M. Rubanyi*
  
- 7      **MIDGE Vectors and dSLIM Immunomodulators:  
DNA-based Molecules for Gene Therapeutic Strategies** 183  
*Manuel Schmidt, Barbara Volz, and Burghardt Wittig*
  
- 8      **Nonprotein-coding RNAs and their Potential as Biopharmaceuticals** 213  
*Maciej Szymanski, Jan Barciszewski and Volker A. Erdmann*
  
- 9      **Double-stranded Decoy Oligonucleotides as new Biopharmaceuticals** 229  
*Andreas H. Wagner and Heiko E. von der Leyen*
  
- 10     **Rational siRNA Design for RNA Interference:  
Optimizations for Therapeutic Use and Current Applications** 243  
*Anastasia Khvorova, Queta Boese, and William S. Marshall*
  
- Mobilis in Mobile – Human Embryonic Stem Cells and Other Sources for Cell Therapy** 269
  
- 11     **The First Cloned Human Embryo: An Unlimited Source of Stem Cells  
for Therapeutic Cloning** 269  
*Woo Suk Hwang, Byeong Chun Lee, Sung Keun Kang, and Shin Yong Moon*
  
- 12     **Myocardial Regeneration Strategies using Human Embryonic Stem Cells** 283  
*Izhak Kehat, Oren Caspi, and Lior Gepstein*
  
- 13     **Gene and Cell-based Therapies for Cardiovascular Disease** 305  
*Abeel A. Mangi*

- 14 **Spheramine®: A Cell Therapeutic Approach to Parkinson's Disease** 325  
*Elke Reissig, Hermann Graf, and Friedrich-Joachim Kapp*

- 15 **Applying Human Cells to Organogenesis and Transplantation** 353  
*Benjamin Dekel and Yair Reisner*

## Volume 2

### Part II Biopharmaceuticals and Their Mode of Action

#### Quid pro Quo – Lysis vs. Coagulation in the Fine-tuned Balance of the Clotting Cascade 377

- 1 **Mechanisms of Serine Proteinase Activation: Insights for the Development of Biopharmaceuticals for Coagulation and Fibrinolysis** 377  
*Rainer Friedrich*

- 2 **Application of the Principle of Polyvalency to Protease Inhibition** 395  
*Luis Moroder*

- 3 **A New Technology Standard for Safety and Efficacy in Factor VIII Replacement Therapy: Designing an Advanced Category rFVIII Concentrate** 419  
*Norbert Riedel and Friedrich Dörner*

#### Errare Humanum Est – What Causes Cancer and How to Selectively Fight Tumors 451

- 4 **Biopharmaceutical Drugs from Natural Sources** 451  
*David J. Newman, Gordon M. Cragg, and Barry R. O'Keefe*

- 5 **Biopharmaceuticals as Targeting Vehicles for *In situ* Radiotherapy of Malignancies** 497  
*Raymond M. Reilly*

- 6 **New Directions in Tumor Therapy – Amino Acid Depletion with GlutaDON® as Treatment for Cancer** 537  
*Rolf Kalhammer and Natarajan Sethuraman*

#### Mundus Vult Decipi – High Mutation Rates of HIV and New Paradigms for Treatment 549

- 7 **AIDS Gene Therapy: A Vector Selectively Able to Destroy Latently HIV-1-infected Cells** 549  
*Francisco Luque Vázquez and Ricardo Oya*

- 8 **Combinatorial RNA-based Therapies for HIV-1** 569  
*Kevin V. Morris and John J. Rossi*



## Part III Improving the Development of Biopharmaceuticals

### Citius, Altius, Fortius – Acceleration by High Throughput and Ultra-HT 583

- 1 **Design of Modern Biopharmaceuticals by Ultra-high-throughput Screening and Directed Evolution** 583  
*Markus Rarbach, Wayne M. Coco, Andre Koltermann, Ulrich Kettling, and Manfred Eigen*
- 2 **Learning from Viruses: High-throughput Cloning using the Gateway® System to Transfer Genes without Restriction Enzymes** 605  
*Jonathan D. Chesnut*

### In Vivo Veritas – Early Target Validation in Knock-out Mice and More 621

- 3 **Target Validation: An Important Early Step in the Development of Novel Biopharmaceuticals in the Post-genomic Era** 621  
*Christoph P. Bagowski*
- 4 **Genetically Modified Mice in Medical and Pharmaceutical Research** 649  
*Cord Brakebusch*
- 5 **An NIH Model Organism for Biopharmaceutical and Biomedical Research: The Lower Eukaryote *Dictyostelium discoideum*** 661  
*Thomas Winckler, Ilse Zündorf, and Theodor Dingermann*

### Revolution by Evolution – Rational Design for Desire and Scientific Art of Optimization 695

- 6 **Releasing the Spring: Cofactor- and Substrate-assisted Activation of Factor IXa** 695  
*Hans Brandstetter and Katrin Sichler*
- 7 **Accelerating Diagnostic Product Development Process with Molecular Rational Design and Directed Evolution** 703  
*Harald Sobek, Rainer Schmuck, and Zhixin Shao*

## Volume 3

### Part IV Production of Biopharmaceuticals

#### The Industry's Workhorses – Mammalian Expression Systems 723

- 1 **Manufacture of Recombinant Biopharmaceutical Proteins by Cultivated Mammalian Cells in Bioreactors** 723  
*Florian M. Wurm*

- 2     **Alternative Strategies and New Cell Lines for High-level Production of Biopharmaceuticals**    761  
*Thomas Rose, Karsten Winkler, Elisabeth Brundke, Ingo Jordan and Volker Sandig*
  
- 3     **PER.C6® Cells for the Manufacture of Biopharmaceutical Proteins**    779  
*Chris Yallop, John Crowley, Johanne Cote, Kirsten Hegmans-Brouwer, Fija Lagerwerf, Rodney Gagne, Jose Coco Martin, Nico Oosterhuis, Dirk-Jan Opstelten, and Abraham Bout*
  
- 4     **Use of the Glutamine Synthetase (GS) Expression System for the Rapid Development of Highly Productive Mammalian Cell Processes**    809  
*John R. Birch, David O. Mainwaring, and Andrew J. Racher*
  
- Vivat, Crescat, Floreat – A Ripe and Blooming Market for Transgenic Animals and Plants**    833
  
- 5     **Biopharmaceuticals Derived from Transgenic Plants and Animals**    833  
*Julio Baez*
  
- 6     **Production of Recombinant Proteins in Plants**    893  
*Victor Klimyuk, Sylvestre Marillonnet, Jörg Knäblein, Michael McCaman, and Yuri Gleba*
  
- 7     **Humanized Glycosylation: Production of Biopharmaceuticals in a Moss Bioreactor**    919  
*Gilbert Gorr and Sabrina Wagner*
  
- 8     **ExpressTec: High-level Expression of Biopharmaceuticals in Cereal Grains**    931  
*Ning Huang and Daichang Yang*
  
- 9     **Biopharmaceutical Production in Cultured Plant Cells**    949  
*Stefan Schillberg, Richard M. Twyman, and Rainer Fischer*
  
- 10    **Producing Biopharmaceuticals in the Desert: Building an Abiotic Stress Tolerance in Plants for Salt, Heat, and Drought**    967  
*Shimon Gepstein, Anil Grover, and Eduardo Blumwald*
  
- 11    **The First Biopharmaceutical from Transgenic Animals: ATryn®**    995  
*Yann Echelard, Harry M. Meade, and Carol A. Ziomek*
  
- Alea Non Lacta Est – Improving Established Expression Systems**    1021
  
- 12    **Producing Modern Biopharmaceuticals: The Bayer HealthCare Pharma Experience with a Range of Expression Systems**    1021  
*Heiner Apeler*

13	<b>Advanced Expression of Biopharmaceuticals in Yeast at Industrial Scale: The Insulin Success Story</b> 1033 <i>Asser Sloth Andersen and Ivan Diers</i>
14	<b>Baculovirus-based Production of Biopharmaceuticals using Insect Cell Culture Processes</b> 1045 <i>Wilfried Weber and Martin Fussenegger</i>
15	<b>Robust and Cost-effective Cell-free Expression of Biopharmaceuticals: Escherichia Coli and Wheat Embryo</b> 1063 <i>Luke Anthony Miles</i>
	<b>When Success Raises its Ugly Head – Outsourcing to Uncork the Capacity Bottleneck</b> 1083
16	<b>Contract Manufacturing of Biopharmaceuticals Including Antibodies or Antibody Fragments</b> 1083 <i>J. Carsten Hempel and Philipp N. Hess</i>
<b>Part V Biopharmaceuticals used for Diagnostics and Imaging</b>	
	<b>From Hunter to Craftsman – Engineering Antibodies with Nature's Universal Toolbox</b> 1105
1	<b>Thirty Years of Monoclonal Antibodies: A Long Way to Pharmaceutical and Commercial Success</b> 1105 <i>Uwe Gottschalk and Kirsten Mundt</i>
2	<b>Modern Antibody Technology: The Impact on Drug Development</b> 1147 <i>Simon Moroney and Andreas Plückthun</i>
3	<b>Molecular Characterization of Autoantibody Responses in Autoimmune Diseases: Implications for Diagnosis and Understanding of Autoimmunity</b> 1187 <i>Constanze Breithaupt</i>
	<b>Find, Fight, and Follow – Target-specific Troika from Mother Nature's Pharmacopoeia</b> 1211
4	<b>Molecular Imaging and Applications for Pharmaceutical R&amp;D</b> 1211 <i>Joke G. Orsel and Tobias Schaeffter</i>
5	<b>Design and Development of Probes for <i>In vivo</i> Molecular and Functional Imaging of Cancer and Cancer Therapies by Positron Emission Tomography (PET)</b> 1243 <i>Eric O. Aboagye</i>
6	<b>Ligand-based Targeting of Disease: From Antibodies to Small Organic (Synthetic) Ligands</b> 1271 <i>Michela Silacci and Dario Neri</i>

- 7     **Ultrasound Theranostics: Antibody-based Microbubble Conjugates as Targeted *In vivo* Contrast Agents and Advanced Drug Delivery Systems** 1301  
*Andreas Briel, Michael Reinhardt, Mathias Mäurer, and Peter Hauff*
- Getting Insight – Sense the Urgency for Early Diagnostics** 1325
- 8     **Development of Multi-marker-based Diagnostic Assays with the ProteinChip® System** 1325  
*Andreas Wiesner*
- 9     **Early Detection of Lung Cancer: Metabolic Profiling of Human Breath with Ion Mobility Spectrometers** 1343  
*Jörg Ingo Baumbach, Wolfgang Vautz, Vera Ruzsanyi, and Lutz Freitag*

## Volume 4

### Part VI Advanced Application Routes for Biopharmaceuticals

#### Getting Inside – Quest for the Best and How to Improve Delivery 1361

- 1     **Advanced Drug Delivery Systems for Biopharmaceuticals** 1361  
*Gesine E. Hildebrand and Stephan Harnisch*
- 1.1   Introduction 1362
- 1.2   Challenges for the Administration of Biopharmaceuticals 1363
- 1.3   Drug Delivery Strategies 1366
- 1.4   Outlook 1384

#### Pathfinder – New Ways for Peptides, Proteins and Co 1393

- 2     **Poly(ethylene) Glycol Conjugates of Biopharmaceuticals in Drug Delivery** 1393  
*Michael D. Bentley, Mary J. Bossard, Kevin W. Burton, and Tacey X. Viegas*
- 2.1   Introduction 1394
- 2.2   The Polymer 1394
- 2.3   Safety and Disposition of PEG 1396
- 2.4   PEG Reagents and Conjugation 1397
- 2.5   Biopharmaceutical Conjugates 1400
- 2.6   PEGylation of Peptides 1407
- 2.7   Formulations of PEGylated Biopharmaceuticals 1408
- 2.8   Analysis of PEG-conjugates 1411
- 2.9   Summary and Future Outlook 1415
- 3     **Novel Vaccine Adjuvants Based on Cationic Peptide Delivery Systems** 1419  
*Karen Lingnau, Christoph Klade, Michael Buschle, and Alexander von Gabain*
- 3.1   Vaccines and their Importance in the Fight against Human Diseases 1420

3.2	<i>Adjuvants: An Overview</i>	1423
3.3	Cationic Peptides as Novel Vaccine Adjuvants	1426
3.4	Cationic Antimicrobial Peptides (CAMP) as Novel Adjuvants	1433
3.5	Cationic Peptide Delivery Systems in Combination with Other Adjuvants	1437
3.6	The Development of IC31 and Future Prospects	1440
3.7	Conclusions	1440
4	<b>The Evolving Role of Oralin™ (Oral Spray Insulin) in the Treatment of Diabetes using a Novel RapidMist™ Diabetes Management System</b>	1445
	<i>Pankaj Modi</i>	
4.1	Introduction	1446
4.2	Rationale for Oralin™ Development	1446
4.3	The Benefits of Oralin™	1447
4.4	The Preparation and Pharmaceutical Properties of Oralin™	1448
4.5	Phase II, Long-term Safety and Efficacy Study	1457
4.6	Conclusions	1460
5	<b>Improvement of Intestinal Absorption of Peptide and Protein Biopharmaceuticals by Various Approaches</b>	1463
	<i>Akira Yamamoto</i>	
5.1	Improvement of Peptide and Protein Absorption	1464
5.2	Use of Protease Inhibitors	1467
5.3	Chemical Modification of Peptide and Protein Biopharmaceuticals	1472
5.4	Chitosan Capsules for the Colon-specific Delivery of Insulin	1480
5.5	Conclusion	1484
	<b>Via Mala – the Stoney Road of DNA Delivery: Back-pack, Feed-back, and Pay-back</b>	1487
6	<b>DNA Vaccine Delivery from Poly(ortho ester) Microspheres</b>	1487
	<i>Chun Wang, Herman N. Eisen, Robert Langer, and Jorge Hellen</i>	
6.1	Introduction	1488
6.2	Poly(Ortho Esters)	1494
6.3	Preparation and Characterization of Microspheres	1496
6.4	<i>In vivo</i> Evaluation of Immune Responses	1500
6.5	Concluding Remarks	1503
7	<b>Liposomal <i>In vivo</i> Gene Delivery</b>	1507
	<i>Shigeru Kawakami, Fumiyoshi Yamashita, and Mitsuru Hashida</i>	
7.1	Cationic Charge-mediated <i>In vivo</i> Gene Transfer to the Lung	1510
7.2	Asialoglycoprotein Receptor-mediated <i>In vivo</i> Gene Transfer to Hepatocytes	1512
7.3	Mannose Receptor-mediated <i>In vivo</i> Gene Transfer to Macrophages	1513
7.4	Folate Receptor-mediated <i>In vivo</i> Gene Transfer to Cancer Cells	1515
7.5	Transferrin Receptor-mediated <i>In vivo</i> Gene Transfer to Brain	1517
7.6	Conclusions	1517

- 8      Programmed Packaging:  
A New Drug Delivery System and its Application to Gene Therapy    1521**  
*Kentaro Kogure, Hidetaka Akita, Hiroyuki Kamiya, and Hideyoshi Harashima*
- 8.1    New Concept for Gene Delivery    1521
- 8.2    Controlled Intracellular Trafficking    1525
- 8.3    Transgene Expression and Gene Correction    1531
- 8.4    Towards Clinical Applications of Transgene Expression  
and Gene Correction    1534

**Getting Beyond – Rocket Science vs. Science Fiction    1537**

- 9      Bionanotechnology and its Role to Improve Biopharmaceuticals    1537**  
*Oliver Kayser*
- 9.1    Introduction    1537
- 9.2    Drug and Gene Delivery    1539
- 9.3    Gene Delivery    1543
- 9.4    Biosensors    1544
- 9.5    Implants and Tissue Engineering    1546
- 9.8    Safety Aspects    1548
- 9.7    Conclusions and Future Trends    1550

**Part VII From Transcription to Prescription of Biopharmaceuticals**

**Dosis Facit Venenum – The Therapeutic Window between Systemic Toxicity  
and Lack of Efficacy    1557**

- 1      Analytics in Quality Control and *In vivo*    1557**  
*Michael Hildebrand*
- 1.1    Introduction    1558
- 1.2    Quality Control    1559
- 1.3    Classes of Biopharmaceuticals    1560
- 1.4    Analytical Methods and Specifications    1560
- 1.5    International Guidelines on Quality Control    1571
- 1.6    Analytics *In vivo*    1573
- 1.7    Conclusions    1577
- 2      Design, Development and Optimization: Crystal Structures  
of Microsomal Cytochromes P450    1581**  
*Dijana Matak Vinković, Sheena Whyte, Harren Jhoti, Jose Cosme,  
and Pamela A. Williams*
- 2.1    P450: The Background    1581
- 2.2    Importance of P450s for Drug Development    1582
- 2.3    Variability and Drug Metabolism    1583
- 2.4    The Structure of Cytochrome P450    1584
- 2.5    Conclusions    1599

- 3     **Mettox™: A Suite of Predictive *In silico* and *In vitro* Assays for Metabolic and Genotoxicological Profiling of Preclinical Drug Candidates**   1603  
       *Michael Murray*
- 3.1   Issues and Economics of Early ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) Assessment   1604
- 3.2   Phase I Metabolism Prediction: Computational Approaches   1608
- 3.3   Phase I Metabolism Prediction: *In vitro* Techniques   1613
- 3.4   Genotoxicity Prediction   1624
- 3.5   Conclusions   1634
- Happy End: Claim to Fame and Approval**   1637
- 4     **Considerations for Developing Biopharmaceuticals: FDA Perspective**   1637  
       *Kurt Brorson, Patrick G. Swann, Janice Brown, Barbara Wilcox, and Marjorie A. Shapiro*
- 4.1   Introduction   1638
- 4.2   Regulatory Authority   1639
- 4.3   Overview of Product Development: CMC Perspective   1643
- 4.4   Chemistry, Manufacturing and Controls Considerations   1645
- 4.5   Quality Control and Assurance   1647
- 4.6   Microbial Issues Specific to Biopharmaceuticals   1650
- 4.7   Process Validation   1653
- 4.8   Inspectional Considerations   1653
- 4.9   Biotech Development:  
       Lessons Learned and Issues Overcome by Industry and FDA   1654
- 4.10   FDA Initiatives to Improve the Pharmaceutical and Biopharmaceutical Development Process   1661
- 5     **The Regulatory Environment for Biopharmaceuticals in the EU**   1669  
       *Axel F. Wenzel and Carina E. A. Sonnega*
- 5.1   Introduction   1673
- 5.2   History and Background   1673
- 5.3   The Competent Regulatory Bodies   1676
- 5.4   What is the EU Authorities' Definition of a Biotechnological Product?   1681
- 5.5   The Regulatory Framework   1682
- 5.6   CP: The "Biotech" Procedure   1683
- 5.7   From Transcription to Prescription:  
       What is Different for Biotechnological Drugs?   1688
- 5.8   Biogenerics   1700
- 5.9   Conclusions and Outlook   1701

## Part VIII From Bench to Bedside – The Aftermaths

### Think Big and Dealmaking for Growth – Global Changes in the Health-care Sector 1711

#### 1 Healthcare Trends and their Impact on the Biopharmaceutical Industry:

##### **Biopharmaceuticals Come of Age 1711**

*Alexander Moscho, Markus A. Schäfer, and Kristin Yarema*

- 1.1 Introduction 1712
- 1.2 Despite Robust Demand the Industry Faces Severe Challenges 1713
- 1.3 Why Biopharmaceuticals can Succeed in Rougher Markets 1724
- 1.4 Biopharmaceutical Players Will Need to Adapt their Portfolios and Business Models 1728
- 1.5 Conclusions and Outlook 1738

### News and Views – Quo Vadis, Biopharmaceuticals? 1741

#### 2 **mondoBIOTECH: The Swiss biotech BOUTIQUE 1741**

*Dorian Bevec and Fabio Cavalli*

- 2.1 Introduction
- 2.2 Product Platforms 1742
- 2.3 Interferon- $\gamma$  + Genechip 1750
- 2.4 Bacteriophages 1751
- 2.5 Outlook for the Company 1752

#### 3 **G-CSF and Bioequivalence: The Emergence of Healthcare Economics 1755**

*James Harris, III*

- 3.1 Introduction 1756
- 3.2 Biogenerics and Bioequivalence 1756
- 3.3 Summary and Outlook 1767

### Light at the End of the Tunnel or Back to the Roots? 1771

#### 4 **Bioinformatics: From Peptides to Profiled Leads 1771**

*Paul Wrede and Matthias Filter*

- 4.1 Introduction 1772
- 4.2 Basic Concepts of Virtual Drug Discovery 1773
- 4.3 Pep2Lead Concept 1778
- 4.4 ADMETox Profiling 1785
- 4.5 Outlook 1798

#### 5 **Engineering and Overproduction of Polyketide Natural Products 1803**

*Martha Lovato Tse and Chaitan Khosla*

- 5.1 Introduction 1804
- 5.2 Polyketide Synthases 1806



5.3	Engineering PKSs to Produce Novel Polyketides	1815
5.4	Development of Scalable Production Processes	1820
5.5	Conclusions	1825

<b>Epilog</b>	1833
---------------	------

<b>More about the Editor</b>	1835
------------------------------	------

<b>Supplement CD-ROM</b>	1837
--------------------------	------

<b>Subject Index</b>	1841
----------------------	------